Paradigm Biopharmaceuticals Advances Clinical Programs

Paradigm Biopharmaceuticals Ltd. (AU:PAR) has released an update.

Paradigm Biopharmaceuticals Ltd. reported significant progress in their Phase 3 Osteoarthritis program after meeting with the US FDA and submitting response documents for review, welcomed a new Non-Executive Director, Matthew Fry, and announced successful Phase 2 trial results for their MPS VI study, showing safety and promising clinical improvements. The company also noted a substantial R&D tax refund of $7.3m and a decrease in quarterly R&D expenditure, with a current cash balance of $26.2m.

For further insights into AU:PAR stock, check out TipRanks’ Stock Analysis page.